Mercado mundial de inhibidores del ciclo celular: tendencias de la industria y pronóstico hasta 2029

Análisis y perspectivas del mercado mundial de inhibidores del ciclo celular

En los últimos años, los avances en el diseño y desarrollo de estudios selectivos y eficientes sobre inhibidores químicos de CDK han llevado al enorme crecimiento y expansión del mercado de inhibidores del ciclo celular. Se prevé que el mercado experimente un crecimiento inmenso durante el período de pronóstico.

• Data Bridge Market Research analiza que el mercado de inhibidores del ciclo celular se valoró en USD 7.31 mil millones en 2021 y se espera que alcance los USD 16.13 mil millones para 2029, registrando una CAGR del 10,40% durante el período de pronóstico de 2022 a 2029. Los "inhibidores de CDK4 e inhibidores de CDK6" representan el segmento de tipos más grande en el mercado de inhibidores del ciclo celular dentro del período previsto.

Definición del mercado mundial de inhibidores del ciclo celular

Los inhibidores del ciclo celular básicamente interrumpen las proteínas de crecimiento para ralentizar o incluso detener la progresión del ciclo celular. La detención del ciclo celular se puede inducir en cualquier momento durante el ciclo celular, lo que ralentiza la división celular y reduce el número de células que realizan un ciclo activo. Los inhibidores del ciclo celular tienen como objetivo atacar la formación de células tumorales en su nivel de raíz, antes de que pueda progresar y afectar a otras células sanas del cuerpo y, en general, hacer que el proceso sea más lento o detener por completo la división celular.

Dinámica del mercado de inhibidores del ciclo celular

Conductores

• Aumento de la incidencia del cáncer

El aumento de la prevalencia del cáncer en todo el mundo provocará una expansión de la tasa de crecimiento del mercado de tratamientos.

Otros

Además, las crecientes inversiones de los gobiernos de varios países en desarrollo a nivel mundial también son determinantes del crecimiento que impulsan el crecimiento del mercado. Además, el aumento del gasto en investigación y desarrollo en la industria farmacéutica son los factores que expandirán el mercado de inhibidores del ciclo celular. La creciente conciencia entre las personas de todo el mundo sobre la disponibilidad de tratamientos para tratar el cáncer de mama afectará positivamente la tasa de crecimiento del mercado de inhibidores del ciclo celular.

Oportunidades

Además, la introducción de tecnologías nuevas e innovadoras junto con la presencia de una sólida cartera de productos clínicos debido a la alta demanda de nuevos medicamentos y terapias impulsará nuevas oportunidades para la tasa de crecimiento del mercado. Asimismo, el aumento de la financiación gubernamental y los programas de concienciación y los avances en tecnología sanitaria acelerarán la tasa de crecimiento del mercado de inhibidores del ciclo celular en el futuro.

Restraints/Challenges Global Cell Cycle Inhibitors Market

However, the high cost of these inhibitors which is not affordable will impede the growth rate of cell cycle inhibitors market. Additionally, the stringent guidelines for the approval is projected to hamper the growth of the market growth.

This cell cycle inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on cell cycle inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

The major purpose of cell cycle inhibitors is to target the tumor cell formation at its root level, before it can progress to affect other healthy cells of the body. Breast cancer is the most common cancer among women, with an estimated 276,000 new cases in 2020.

Cell cycle inhibitors market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Covid-19 Impact on Cell Cycle Inhibitors Market

Healthcare and pharmaceutical industries were heavily impacted by the COVID-19. The closure of commercial activities due to the restrictive containment measures, resulted in operational challenges for the cell cycle inhibitors market and affected the market negatively. The implementation of strict lockdowns and isolation regulations across the globe further complicated the disease management and medication adherence and even further caused delays in the import and export of drugs as the entire supply chain has been disrupted.

However, the companies are resuming operations and adapting to the new normal as they recover from the COVID-19 impact, which will lead to the surge in the market’s growth to the pre-pandemic level.

Recent Developments

• In Oct 2021,  Abemaciclib by Verzenio, Eli Lilly and Company was approved by FDA with endocrine therapy for adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, early breast cancer and node-positive. It is the first CDK 4/6 inhibitor approved for adjuvant treatment of breast cancer.

Global Cell Cycle Inhibitors Market Scope

The cell cycle inhibitors market is segmented on the basis of types, application, route of administration, end-user and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• CDK4 Inhibitors
• CDK9 Inhibitors
• CDK6 Inhibitors
• Others

On the basis of types, cell cycle inhibitors market is segmented into CDK4 inhibitors, CDK9 inhibitors, CDK6 inhibitors and others. CDK4 Inhibitors and CDK6 Inhibitors are estimated to grow largely within the segment as both of them are approved by the FDA to treat breast cancer.

Application

• Breast Cancer
• Hematological Malignancies
• Others

On the basis of application, cell cycle inhibitors market is segmented into breast cancer, hematological malignancies and others.

Route of Administration

• Oral
• Intravenous
• Others

On the basis of route of administration, the cell cycle inhibitors market is segmented into oral, intravenous and others.

End-User

• Hospitals
• Specialty Clinics
• Others

On the basis of end-users, the cell cycle inhibitors market is segmented into hospitals, specialty clinics and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

On the basis of distribution channel, the cell cycle inhibitors market is segmented into hospital pharmacy, retail pharmacy and others.

Cell Cycle Inhibitors Market Regional Analysis/Insights

The cell cycle inhibitors market is analyzed and market size insights and trends are provided by country, types, application, route of administration, end-user and distribution channel as referenced above.

The countries covered in the cell cycle inhibitors market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific dominates the cell cycle inhibitors market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the increasing prevalence of cancer cases in this region.

Europe on the other hand is projected to exhibit the highest growth rate during the forecast period due to the focus of global players on novel technology in the region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Cell Cycle Inhibitors Market Share Analysis

The cell cycle inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cell cycle inhibitors market.

Some of the major players operating in the cell cycle inhibitors market are Sanofi, Syros Pharmaceuticals, Inc., Piramal Enterprises Ltd., Pfizer Inc., NMS Group SpA, G1 Therapeutics, Inc., Eli Lilly and Company, Cyclacel Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., Teva Pharmaceuticals Industries Ltd., Sanofi, Genentech, Inc., Sanofi Regeneron Pharmaceuticals,  BioCAD GLOBAL, Bayer AG, Otsuka America, Inc., Amgen Inc., and ANYGEN among others.

Research Methodology : Global Cell Cycle Inhibitors Market

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con tamaños de muestra grandes. Los datos del mercado se analizan y estiman utilizando modelos estadísticos y coherentes del mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta. La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Aparte de esto, los modelos de datos incluyen la cuadrícula de posicionamiento de proveedores, el análisis de la línea de tiempo del mercado, la descripción general y la guía del mercado, la cuadrícula de posicionamiento de la empresa, el análisis de la participación de mercado de la empresa, los estándares de medición, el análisis global versus regional y la participación de los proveedores. Para saber más sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria  https://www.databridgemarketresearch.com/es/speak-to-analyst/?dbmr=global-cell-cycle-inhibitors-market

SKU-52995